Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation
- 30 September 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 69 (10), 1947-1958
- https://doi.org/10.1007/s00262-020-02646-0
Abstract
Objectives Scientific advances in the last decade have highlighted the use of immunotherapy, especially immune checkpoint inhibitors, to be an effective strategy in cancer therapy. However, these immunotherapeutic agents are expensive, and their use must take into account economic criteria. Thus, the objective of the present study was to systematically identify and review published EE related to the use of ipilimumab, nivolumab or pembrolizumab in melanoma, lung cancer, head and neck cancer or renal cell carcinoma, and to assess their quality. Methods The systematic literature research was conducted on Medline via PubMed and the Cochrane Central Register of Controlled Trials to identify economic evaluations published before July 2018. The quality of each selected economic evaluation was assessed by two independent reviewers using the Drummond checklist. Results Our systematic review was based on 32 economic evaluations using different methodological approaches, different perspectives and different time horizons. Three-quarters of the economic evaluations are full (n = 24) with a Drummond score >= 7, synonymous of "high quality". Among them, 66% reported a strategy that was cost-effective. The most assessed immunotherapeutic agent was nivolumab. In patients with renal cell carcinoma or head and neck cancer, it was less likely to be cost-effective than in patients with melanoma or lung cancer. Conclusions Whether or not these findings will be confirmed remains to be seen when market approval to cover more indications is extended and new effective immunotherapeutic agents become available.This publication has 54 references indexed in Scilit:
- Pembrolizumab versus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2015
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trialThe Lancet Oncology, 2015
- Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic MelanomaPLOS ONE, 2014
- Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savingsJournal of Oncology Pharmacy Practice, 2013
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysisJournal of Medical Economics, 2012
- Immuno-oncology: understanding the function and dysfunction of the immune system in cancerAnnals of Oncology, 2012
- Health outcomes in economic evaluation: the QALY and utilitiesBritish Medical Bulletin, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996